TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Care Management for the Effective Use of Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Veterans will be eligible if they have:~* chronic lower back pain of at least moderate intensity~* pain for 6 months~* on chronic opioid therapy~* and access to a working telephone~Exclusion Criteria:~Exclusion criteria includes:~* severe medical conditions~* active psychosis~* schizophrenia~* active suicidal ideation~* pending back surgery~* moderately severe cognitive impairment~* involvement in ongoing pain trials~* and pregnant or trying to become pregnant~The investigators will exclude Veterans with an active substance use disorder (i.e., those currently in treatment), but to maximize generalizability the investigators will not exclude those with a past history of substance abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Pharmacological (MED) (Type: EXPERIMENTAL): Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
- Arm 2: Behavioral treatment (CBT) (Type: EXPERIMENTAL): Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients with penetrating eye injuries referred to collaborating institutes for primary repair~Exclusion Criteria:~* Absence of light perception~* presence of endophthalmitis at the time of initial evaluation~* total corneal opacity~* age under 3 years~* severe intracameral hemorrhage~* history of intraocular surgery and presence of a corneal ulcer~* Monocular patients~* the better eye in simultaneous bilateral injuries

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Side Effects of Atropine (SEA) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-N/A~Exclusion Criteria:~* Outside of age range~* History of accommodative (focusing) issues or therapy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- One Week Atropine (Type: EXPERIMENTAL): 0.01% concentration atropine drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
FURTHER STUDY DETAILS PROVIDED BY KALA PHARMACEUTICALS, INC.~Inclusion Criteria:~* Candidates for routine, uncomplicated cataract surgery~* In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.~Exclusion Criteria:~* Known hypersensitivity/contraindication to study product(s) or components.~* History of glaucoma, IOP \>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.~* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 19 days following surgery.~* In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KPI-121 0.25% QID (Type: ACTIVE_COMPARATOR): KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
- KPI-121 1.0% BID (Type: ACTIVE_COMPARATOR): KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
- Vehicle of KPI-121 0.25% (Type: PLACEBO_COMPARATOR): Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
- Vehicle of KPI-121 1.0% (Type: PLACEBO_COMPARATOR): Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With SU11248 in Patients With Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor.~* Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).~* ECOG performance status 0 or 1~Exclusion Criteria:~* Diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri.~* Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 4 patients~* Older than 18 years of age~* Non-diabetic~* Serum phosphorus \> 5.5 mg/dl~Exclusion Criteria:~* Diabetes mellitus~* History of coronary artery disease~* Smokers~* Taking statins or renin-angiotensin blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sevelamer (Type: OTHER): None
- calcium acetate (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin in New Onset Diabetes After Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Newly diagnosed NODAT defined by pathologic OGTT (2h, 75mg glucose): glucose ≥ 200mg/dl~* renal transplantation (deceased or living donor) and treatment with the standard immunosuppression at our center, consisting of triple therapy with tacrolimus or cyclosporine A, mycophenolate mofetil or azathioprine, and prednisone.~* stable graft function for more than 6 months post transplant.~* informed consent of the patient~Exclusion Criteria:~* patients with prior history of type 1 or type 2 diabetes~* body mass index (BMI) \> 40~* pregnancy~* severe renal impairment (GFR \< 30 mL/min./1.73 m2)~* severe liver impairment~* severe blood glucose elevation with the need for therapy with insulin or HbA1c \>8.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin, 50 mg, peroral (Type: ACTIVE_COMPARATOR): None
- Placebo pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Virginal Female Subject Aged 9 To 17 Years~Exclusion Criteria:~* Male Subject

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle \[VLP\] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of active CNV secondary to any causes with the CNV or its sequelae affecting the fovea;~* BCVA must be between ≥ 24 and ≤ 83 letters in the study eye;~* Visual loss in the study eye should mainly be due to the presence of any eligible types of CNV;~Key Exclusion Criteria:~* Women of child-bearing potential;~* Active malignancies;~* History of stroke less than 6 months prior to screening;~* Uncontrolled systemic inflammation or infection;~* Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;~* CNV- conditions with a high likelihood of spontaneous resolution;~* History of intravitreal treatment with steroids;~* History of laser photocoagulation;~* History of intraocular treatment with any anti-angiogenic drugs.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
- Sham control (Type: SHAM_COMPARATOR): Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained~* Subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of the previously mentioned compounds~* HbA1c 7.0-10.0% (both inclusive)~* Body Mass Index (BMI) at least 27.0 kg/m\^2~* Stable body weight~* Preceding failed dietary effort~Exclusion Criteria:~* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months~* Known proliferative retinopathy or maculopathy~* History of acute or chronic pancreatitis~* Obesity induced by drug treatment~* Use of approved weight lowering pharmacotherapy~* Previous surgical treatment of obesity~* History of major depressive disorder or suicide attempt~* Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Screening calcitonin of 50 ng/L or above~* Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)~* Personal history of non-familial medullary thyroid carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lira 3.0 mg (Type: EXPERIMENTAL): None
- Lira 1.8 mg (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Tear film assessment that qualifies in both eyes~* Evidence of meibomian gland dysfunction and dry eye in both eyes~* Willingness to comply with study protocol~Exclusion Criteria:~* Systemic disease condition or medication that causes dry eye~* Use of other treatments for MGD or dry eye~* Ocular surgery, trauma, herpes infection, punctal plug insertion or punctal occlusion within past 3 months~* Active eye infection~* Active eye inflammation or recurrent inflammation within past 3 months~* Moderate to severe allergic conjunctivitis~* Severe eyelid inflammation~* Eyelid abnormality that affects lid function~* Ocular surface abnormality that may compromise corneal integrity~* Pregnant or nursing women~* Participation in another ophthalmic clinical trial within past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LipiFlow System (Type: EXPERIMENTAL): Treatment with LipiFlow System at randomization in Stage 1 of study
- Warm Compress and Lid Hygiene (Type: ACTIVE_COMPARATOR): Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No fever on day of vaccination~* Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal~* Underlying chronic illness must be stable~Exclusion Criteria:~* History of hypersensitivity reaction to any vaccine component~* Prior history of herpes zoster~* Prior receipt of varicella or zoster vaccine~* Pregnant or breastfeeding~* Have recently received immunoglobulins or blood products other than autologous blood transfusion~* Received any inactivated other live virus vaccine within 4 weeks prior to vaccination, or is expected to received any other live virus vaccine during the duration of the study~* Received any inactivated vaccine within 7 days prior to vaccination, or is expected to receive any inactivated vaccine during the duration of the study~* Use of immunosuppressive therapy~* Known or suspected immune dysfunction~* Use of nontopical antiviral therapy with activity against herpes virus~* Known or suspected active untreated tuberculosis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zoster Vaccine Live (Type: EXPERIMENTAL): Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xenon in Off-pump Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with coronary artery disease scheduled for elective OPCAB- surgery~* Patients willing and able to complete the requirements of this study~* Ejection Fraction \> 30%~Exclusion Criteria:~* Lack of informed consent~* Age \< 18 years~* Pregnancy~* chronic obstructive pulmonary disease (COPD) GOLD \> II~* Renal dysfunction defined as serum-creatinine \> 1.5 mg/dl~* Acute coronary syndrome during the last 24 hours; haemodynamic instability, requirement of inotropic support~* Single vessel grafting~* Disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease, schizophrenia, depression), history of stroke with residuals, significant stenosis of carotid arteries, increased intracranial pressure~* Hypersensitivity to the study medication~* Presumed uncooperativeness or legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Xenon (Type: EXPERIMENTAL): gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
- Drug: Sevoflurane (Type: ACTIVE_COMPARATOR): inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have best corrected visual acuity in both eyes of at least +0.7 or better~* Central corneal staining of 3 on the NEI scale~* If female, are non-pregnant or non-lactating~* Have a history of dry eye disease in both eyes~* Have normal lid anatomy~Exclusion Criteria:~* Unable to withhold the use of contact lenses during the study or 2 weeks prior to the study~* Have had ocular surface surgery within the past year~* Are considered legally blind in one eye~* Have a serious medical condition which could confound study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 2 (Type: PLACEBO_COMPARATOR): None
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete